Resverlogix Corp. (RVXCF)

[noretreat]

stock is on a nice trend...it has continued even though it has gotten overheated a couple of times. The change occurred at the end of May and has continued since then, with the price well above the 50 and the 50 crossing the 200 early in July.

This will continue through the topline unless there is a negative SSRA. Chances of that are slim right now.

Funding through the topline and a bit beyond is no longer an issue...hallelujah to that accomplishment.

My only question right now is: Why the recent focus on apabetalone and dementia/AD? Not sure I get the rationale for that at this stage of BetOnMace. Clearly, sub-group analysis is important but at this stage it almost feels like reaching for a "back-up" finding in case the MACE reduction is less than 30% and it misses the primary endpoint.